Maximum Dose of Extended-Release Adderall
The maximum recommended dose of extended-release Adderall (mixed amphetamine salts XR) is 40 mg once daily for adolescents and adults, though the FDA label references a maximum of 30 mg/day for children in safety studies. 1
Dosing by Age Group
Children (6-12 years)
- The FDA label references a maximum recommended human dose of 30 mg/day in children based on safety and carcinogenicity studies 1
- Amphetamines are not recommended for children under 3 years of age 1
Adolescents (13-17 years) and Adults
- Maximum dose: 40 mg once daily 2
- Clinical trial data in adolescents demonstrated efficacy and tolerability up to 40 mg/day using forced-dose titration over 4 weeks 2
- In adults, doses up to 60 mg/day have been studied in long-term safety trials (24 months), though this exceeds typical maximum recommendations 3
Dosing Algorithm
Start low and titrate based on response:
- Initial dose: 10-20 mg once daily in the morning
- Titration: Increase by 10 mg weekly intervals based on clinical response
- Target dose: 20-30 mg/day for most patients
- Maximum dose: 40 mg/day (standard maximum); rarely 60 mg/day in adults under specialist supervision
Critical Safety Considerations
Cardiovascular monitoring is essential - amphetamines consistently increase blood pressure (SBP by ~2 mmHg, DBP by ~2 mmHg) and heart rate (by ~4 bpm), with these effects sustained over time 4. Monitor pulse and blood pressure at baseline and with each dose adjustment 5.
Common pitfalls to avoid:
- Prolonged high-dose use carries cardiomyopathy risk - chronic amphetamine exposure can cause structural cardiac abnormalities through oxidative stress and sympathetic overactivity 6
- Diversion risk in adolescents - consider non-stimulant alternatives (atomoxetine, extended-release guanfacine/clonidine) in high-risk populations 7
- Withdrawal rates increase with dose - patients on amphetamines are 2.7 times more likely to withdraw due to adverse effects compared to placebo 4
Most common adverse effects limiting dose escalation include decreased appetite (35.6%), insomnia (12%), headache (16%), and abdominal pain (11%) 2. Weight loss occurs in 9.4% of patients 2.
Special Populations
- Preschool children: Maximum doses not adequately studied; use only in moderate-to-severe ADHD with extreme caution 7
- Geriatric patients: Adderall has not been studied in this population 1
- Pregnancy: Use only if potential benefit justifies risk; associated with premature delivery and low birth weight 1